The $3.4 Billion Lesson Pharma Faces in Shelved Drugs
Thousands of shelved drug candidates could unlock therapies for rare diseases, but funding and partnerships lag. The ...
This article outlines a withdrawal framework using index funds and bonds, covering order of withdrawals, sequence risk, and practical steps.
28,655 articlesThousands of shelved drug candidates could unlock therapies for rare diseases, but funding and partnerships lag. The ...
A political shift in the United States is denting confidence in mRNA medicine, with funding drying up and manufacturi...
Powell will continue to serve on the Federal Reserve Board after his chair term ends next month, steering a measured ...
Analysts project NVIDIA’s free cash flow to climb sharply as AI deployments accelerate, potentially changing how inve...
SpaceX is exploring an IPO designed for everyday investors, outlining a plan to list shares and fund its space infras...
A courtside hug at a Knicks game becomes more than a moment in sports headlines. This guide turns that scene into rea...
SpaceX signals a potential $75 billion IPO, elevating CFO Bret Johnsen to the center of a new phase focused on govern...
Solstice and TensorX unveil a financing pact to fund up to $1 billion in European sovereign AI infrastructure, using ...
Cerebras is grabbing headlines as traders push the stock higher on momentum rather than news. This guide breaks down ...
The spotlight in AI investing is shifting from screens to factories. The BOTZ ETF is positioning itself to ride a wav...
The Washington Post has canceled Book World, delivering a major shake-up in literary coverage. Readers bid farewell a...
A recent OpenAI scare revealed how quickly powerful AI can breach safeguards. The event is prompting regulators and i...